Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference

Rifaquat Rahman; Mei-Yin C Polley; Laura Alder; Priscilla K Brastianos; Carey K Anders; Hussein A Tawbi; Minesh Mehta; Patrick Y Wen; Susan Geyer; John de Groot; Gelareh Zadeh; Steven Piantadosi; Evanthia Galanis; Mustafa Khasraw

doi:10.1016/S1470-2045(23)00005-0

Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference

Rifaquat Rahman, Mei-Yin C Polley, Laura Alder, Priscilla K Brastianos, Carey K Anders, Hussein A Tawbi, Minesh Mehta, Patrick Y Wen, Susan Geyer, John de Groot, Gelareh Zadeh, Steven Piantadosi, Evanthia Galanis, Mustafa Khasraw

Miami Cancer Institute

Research output: Contribution to journal › Review article › peer-review

Abstract

Successful drug development for people with cancers of the CNS has been challenging. There are multiple barriers to successful drug development including biological factors, rarity of the disease, and ineffective use of clinical trials. Based upon a series of presentations at the First Central Nervous System Clinical Trials Conference hosted by the American Society of Clinical Oncology and the Society for Neuro-Oncology, we provide an overview on drug development and novel trial designs in neuro-oncology. This Review discusses the challenges of therapeutic development in neuro-oncology and proposes strategies to improve the drug discovery process by enriching the pipeline of promising therapies, optimising trial design, incorporating biomarkers, using external data, and maximising efficacy and reproducibility of clinical trials.

Original language	English
Pages (from-to)	e161-e171
Journal	The Lancet Oncology
Volume	24
Issue number	4
DOIs	https://doi.org/10.1016/S1470-2045(23)00005-0
State	Published - Mar 2023

Keywords

Humans
Reproducibility of Results
Neoplasms/drug therapy
Medical Oncology
Societies, Medical
Drug Development

Access to Document

10.1016/S1470-2045(23)00005-0

Cite this

Rahman, R., Polley, M.-Y. C., Alder, L., Brastianos, P. K., Anders, C. K., Tawbi, H. A., Mehta, M., Wen, P. Y., Geyer, S., de Groot, J., Zadeh, G., Piantadosi, S., Galanis, E., & Khasraw, M. (2023). Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference. The Lancet Oncology, 24(4), e161-e171. https://doi.org/10.1016/S1470-2045(23)00005-0

Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference. / Rahman, Rifaquat; Polley, Mei-Yin C; Alder, Laura et al.
In: The Lancet Oncology, Vol. 24, No. 4, 03.2023, p. e161-e171.

Research output: Contribution to journal › Review article › peer-review

Rahman, R, Polley, M-YC, Alder, L, Brastianos, PK, Anders, CK, Tawbi, HA, Mehta, M, Wen, PY, Geyer, S, de Groot, J, Zadeh, G, Piantadosi, S, Galanis, E & Khasraw, M 2023, 'Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference', The Lancet Oncology, vol. 24, no. 4, pp. e161-e171. https://doi.org/10.1016/S1470-2045(23)00005-0

@article{4f232ed7c7654ad499388791fcda5c75,

title = "Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference",

abstract = "Successful drug development for people with cancers of the CNS has been challenging. There are multiple barriers to successful drug development including biological factors, rarity of the disease, and ineffective use of clinical trials. Based upon a series of presentations at the First Central Nervous System Clinical Trials Conference hosted by the American Society of Clinical Oncology and the Society for Neuro-Oncology, we provide an overview on drug development and novel trial designs in neuro-oncology. This Review discusses the challenges of therapeutic development in neuro-oncology and proposes strategies to improve the drug discovery process by enriching the pipeline of promising therapies, optimising trial design, incorporating biomarkers, using external data, and maximising efficacy and reproducibility of clinical trials.",

keywords = "Humans, Reproducibility of Results, Neoplasms/drug therapy, Medical Oncology, Societies, Medical, Drug Development",

author = "Rifaquat Rahman and Polley, {Mei-Yin C} and Laura Alder and Brastianos, {Priscilla K} and Anders, {Carey K} and Tawbi, {Hussein A} and Minesh Mehta and Wen, {Patrick Y} and Susan Geyer and {de Groot}, John and Gelareh Zadeh and Steven Piantadosi and Evanthia Galanis and Mustafa Khasraw",

year = "2023",

month = mar,

doi = "10.1016/S1470-2045(23)00005-0",

language = "English",

volume = "24",

pages = "e161--e171",

journal = "The Lancet Oncology",

issn = "1470-2045",

number = "4",

}

TY - JOUR

T1 - Current drug development and trial designs in neuro-oncology

T2 - report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference

AU - Rahman, Rifaquat

AU - Polley, Mei-Yin C

AU - Alder, Laura

AU - Brastianos, Priscilla K

AU - Anders, Carey K

AU - Tawbi, Hussein A

AU - Mehta, Minesh

AU - Wen, Patrick Y

AU - Geyer, Susan

AU - de Groot, John

AU - Zadeh, Gelareh

AU - Piantadosi, Steven

AU - Galanis, Evanthia

AU - Khasraw, Mustafa

PY - 2023/3

Y1 - 2023/3

N2 - Successful drug development for people with cancers of the CNS has been challenging. There are multiple barriers to successful drug development including biological factors, rarity of the disease, and ineffective use of clinical trials. Based upon a series of presentations at the First Central Nervous System Clinical Trials Conference hosted by the American Society of Clinical Oncology and the Society for Neuro-Oncology, we provide an overview on drug development and novel trial designs in neuro-oncology. This Review discusses the challenges of therapeutic development in neuro-oncology and proposes strategies to improve the drug discovery process by enriching the pipeline of promising therapies, optimising trial design, incorporating biomarkers, using external data, and maximising efficacy and reproducibility of clinical trials.

AB - Successful drug development for people with cancers of the CNS has been challenging. There are multiple barriers to successful drug development including biological factors, rarity of the disease, and ineffective use of clinical trials. Based upon a series of presentations at the First Central Nervous System Clinical Trials Conference hosted by the American Society of Clinical Oncology and the Society for Neuro-Oncology, we provide an overview on drug development and novel trial designs in neuro-oncology. This Review discusses the challenges of therapeutic development in neuro-oncology and proposes strategies to improve the drug discovery process by enriching the pipeline of promising therapies, optimising trial design, incorporating biomarkers, using external data, and maximising efficacy and reproducibility of clinical trials.

KW - Humans

KW - Reproducibility of Results

KW - Neoplasms/drug therapy

KW - Medical Oncology

KW - Societies, Medical

KW - Drug Development

U2 - 10.1016/S1470-2045(23)00005-0

DO - 10.1016/S1470-2045(23)00005-0

M3 - Review article

C2 - 36990614

SN - 1470-2045

VL - 24

SP - e161-e171

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 4

ER -